TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33349011
Drug: Mg+H2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg+H2
Study: 33349011
Drug: Mg and
Normalized name: Vraylar 1.5mg and 3mg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg and Mg+H2
Study: 32255542
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg esaxerenone
Study: 32255542
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg esaxerenone
Study: 35085663
Drug: Allergen immunotherapy
Normalized name: Allergen immunotherapy extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen immunotherapy (subcutaneous and sublingual) continued for a minimum of 3 years
Study: 35085663
Drug: Grass pollen
Normalized name: grass pollen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grass pollen immunotherapy for seasonal rhinitis
Study: 35085663
Drug: Mite sublingual
Normalized name: mite,D.farinae-D.pteronyssinus 12 standardized quality-house dust mite SUBLINGUAL TABLET, SUBLINGUAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mite sublingual immunotherapy
Study: 37275956
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone ointment
Study: 33181557
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg·kg‐1
Study: 33181557
Drug: Propacetamol 30
Normalized name: Propanetriol
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 30 mg·kg‐1
Study: 33181557
Drug: Ibuprofen 10
Normalized name: ibuprofen 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 10 mg·kg‐1 + Propacetamol 30 mg·kg‐1
Study: 32787932
Drug: Group Interpersonal
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Interpersonal Therapy (IPT) adapted for adolescents; delivered in secondary schools by school nurses and lay community members; includes parental engagement components and locally acceptable terms for mental illness.
Study: 35546458
Drug: Coconut cream
Normalized name: ALCOHOL 620 mg in 1 mL TOPICAL LIQUID [TOPCARE COCONUT CREAM]
DrugBank: Coconut (DB10523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coconut cream 50%
Study: 34247834
Drug: Real world
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real world data as a comparator for single-arm treatment trials
Study: 34806331
Drug: Progesterone soft
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone soft capsule under fasting conditions
Study: 34806331
Drug: Progesterone soft
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Progesterone soft capsule under fed conditions (high-fat meal, 890 kcal)
Study: 34626515
Drug: Bortezomib (Btz)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib (Btz) in combination with melphalan and prednisolone (MPB)
Study: 33066974
Drug: SSRI exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRI exposure (fluoxetine, sertraline, escitalopram/citalopram)
Study: 33066974
Drug: Fluoxetine exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine exposure
Study: 34043621
Drug: Mosquito Exposure
Normalized name: mosquito allergenic extract
DrugBank: Aedes taeniorhynchus (DB10691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mosquito Exposure Index (MEI) measured by ELISA for anti-Aedes saliva antibodies
Study: 32182219
Drug: VRC01 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VRC01 infusion
Study: 35193729
Drug: Cariprazine 6
Normalized name: cariprazine 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 6 mg/d
Study: 32297352
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care plus 2-weekly home end-of-life and palliative care coaching by experienced community nurses
Study: 39117415
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg daily aspirin
Study: 39117415
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg daily aspirin
Study: 36373571
Drug: man therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: man therapy (MT)
Study: 34007070
Drug: CoVLP (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoVLP (3.75 μg, 7.5 μg, and 15 μg)
Study: 32568399
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride (n = 176)
Study: 32568399
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine hydrochloride (n = 180)
Study: 33386332
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 9vHPV vaccine (0, 6 regimen)
Study: 33386332
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of 9vHPV vaccine (0, 12 regimen)
Study: 33386332
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of 9vHPV vaccine (0, 2, 6 regimen)
Study: 34189463
Drug: Bevacizumab therapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab therapy
Study: 33636356
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline Solution (NSS)
Study: 33636356
Drug: Savlon Solution
Normalized name: Savlon Dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savlon Solution
Study: 35575284
Drug: Hochuekkito administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hochuekkito administration
Study: 35575284
Drug: Control (non-hochuekkito
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-hochuekkito administration)
Study: 33724513
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (specific treatment not detailed)
Study: 33253833
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab (IXE) 80 mg every 2 weeks
Study: 33253833
Drug: Ixekizumab (IXE)
DrugBank: Ixekizumab (DB11569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ixekizumab (IXE) 80 mg every 4 weeks
Study: 36307361
Drug: Botulinum Toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum Toxin A (BTA) - 50 units injected twice, 3 months apart
Study: 34169543
Drug: AUC estimated
Approvals — FDA: no, EMA: no, PMDA: no
Description: AUC estimated from trough-only data using derived volume of distribution (Vd) equation: Vd (L) = 0.29(age) + 0.33(total BW in kg) + 11
Study: 34706949
Drug: Average treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Average treatment effect of CRT response
Study: 32628039
Drug: Capillary microsampling
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capillary microsampling of 15 μl whole blood from fingersticks or heelsticks in a respiratory syncytial virus drug study
Study: 34861685
Drug: Granulox therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granulox therapy twice weekly
Study: 34861685
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (once-weekly podiatric medical clinic visits)
Study: 32574138
Drug: Caregiver concerns
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caregiver concerns for MMR vaccine
Study: 34768692
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no biofeedback therapy)
Study: 32400227
Drug: No past
Approvals — FDA: no, EMA: no, PMDA: no
Description: No past month drug use
Study: 35749253
Drug: Etelcalcetide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide plus oral calcium (E+Ca group)
Study: 34342134
Drug: Rectal spacer
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal spacer
Study: 34342134
Drug: No rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rectal spacer
Study: 36229113
Drug: Behavioral Experiments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Experiments for Intolerance of Uncertainty (12 weekly 1-hour sessions)
Study: 37757502
Drug: Specialized oral
Normalized name: epinephrine / mepivacaine hydrochloride Injectable Solution [Scandonest 2% Special]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specialized oral nutritional supplement (S-ONS)
Study: 35421949
Drug: Focused Acceptance
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused Acceptance and Commitment Therapy (FACT-CP)
Study: 35233271
Drug: FES-cycling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FES-cycling and standard treatment
Study: 35233271
Drug: Sham stimulus
Normalized name: Limulus polyphemus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham stimulus FES-cycling and standard treatment
Study: 33099752
Drug: Ropeginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon alfa‐2b 350 μg (group 1)
Study: 33099752
Drug: Ropeginterferon alfa‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropeginterferon alfa‐2b 450 μg (group 2)
Study: 33099752
Drug: PEG‐IFN alfa‐2a
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN alfa‐2a 180 μg (group 3)
Study: 34004418
Drug: Sulforaphane (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulforaphane (30 mg/d)
Study: 33963594
Drug: 8-week multimodal
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week multimodal intervention (ATENTO) prior to adjuvant chemotherapy (ATENTO-B)
Study: 33963594
Drug: 8-week multimodal
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8-week multimodal intervention (ATENTO) throughout adjuvant chemotherapy (ATENTO-T)
Study: 34763599
Drug: Heat-stable carbetocin
Normalized name: (9-L-TYROSINE)HEAT-STABLE ENTEROTOXIN (ESCHERICHIA COLI)-(6-19)-PEPTIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-stable carbetocin 100 μg IM
Study: 34933316
Drug: Povidone‐iodine in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone‐iodine in aqueous solution
Study: 32220595
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/mL solution in Mucolox (arm A)
Study: 32220595
Drug: Dexamethasone 0.1
Normalized name: dexamethasone 0.15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 0.1 mg/mL solution alone (arm B)
Study: 36301019
Drug: Fentanyl (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (25 µg) with 0.5% hyperbaric bupivacaine (3 mL)
Study: 36301019
Drug: Nalbuphine (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine (0.8 mg) with 0.5% hyperbaric bupivacaine (3 mL)
Study: 35707866
Drug: Oral tomato
Normalized name: Tomato
DrugBank: Tomato (DB10573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tomato extract supplement containing lycopene 30 mg
Study: 34444764
Drug: Mangosteen and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mangosteen and propolis extracts (MAEC) - daily intake of a single capsule containing 194 mg for eight weeks
Study: 35960141
Drug: Acupuncture with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture with additional manual-movement or mind–body CIM therapies (group B)
Study: 32412314
Drug: 5% minoxidil
Normalized name: MINOXIDIL 5 g in 100 mL TOPICAL LIQUID [ASDTOTIO 5% minoxidil]
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% minoxidil twice daily for 24 weeks
Study: 32412314
Drug: Microneedle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedle therapy every 3 weeks for eight treatments
Study: 32412314
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of microneedling and 5% minoxidil for a total of 24 weeks
Study: 32186395
Drug: PPI +
Normalized name: PPI-1040
DrugBank: PPI-1040 (DB17620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPI + mucolytics
Study: 35332542
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT)-based group counseling
Study: 34025683
Drug: Mastiha supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mastiha supplementation (2.1 g/day) for 6 months
Study: 33471961
Drug: Lower milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower milk consumption (<220 g/day)
Study: 32627052
Drug: High flavanol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flavanol (HF) chocolate bar (1060 mg)
Study: 32627052
Drug: Moderate flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate flavanol (MF) chocolate bar (746 mg)
Study: 32627052
Drug: Low flavanol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low flavanol (LF) chocolate bar (406 mg)
Study: 32627052
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) chocolate bar (88 mg)
Study: 38583091
Drug: High-dose trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose trivalent inactivated influenza vaccine
Study: 32541370
Drug: Citicoline eyedrops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline eyedrops 3 times daily for 3 years
Study: 32541370
Drug: Placebo 3
Normalized name: placebo 330 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 3 times daily for 3 years
Study: 32367180
Drug: Rituximab (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rituximab (375 mg/m2, four weekly infusions)
Study: 34196632
Drug: Multimedia Psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimedia Psychotherapy (with psycho-pharmacological therapy)
Study: 34196632
Drug: Psycho-pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-pharmacological therapy and Multimedia Psychotherapy
Study: 35754298
Drug: Pertuzumab, trastuzumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pertuzumab, trastuzumab, and physician's choice chemotherapy (PTC)
Study: 35754298
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and physician's choice chemotherapy (TC)
Study: 32721104
Drug: Nicotinamide (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotinamide (1.5 g/day for 6 weeks, then 3.0 g/day for 6 weeks)
Study: 34802729
Drug: Bupivacaine liposome
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine liposome suspension block, oral placebo (BUP)
Study: 34802729
Drug: Lidocaine block,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine block, oral placebo (LID)
Study: 34802729
Drug: Lidocaine block,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine block, oral meloxicam (1 mg/kg of body weight; LID + MEL)
Study: 34802729
Drug: Saline block,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline block, oral placebo (CON)
Study: 34802729
Drug: Saline block,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline block, oral placebo, sham dehorn (SHAM)
Study: 33220141
Drug: Bonding agent
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonding agent (Adper™ Single Bond 2, 3M ESPE) applied before sealant application (Helioseal®clear, Ivoclar Vivadent)
Study: 35449008
Drug: STRONG programme
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRONG programme (≥6 weekly sessions with patient education, motivational and pharmaceutical support)
Study: 33780423
Drug: NeuroEPO (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroEPO (1 mL, at a concentration of 1 mg/mL) administered intranasally once a week for 5 weeks
Study: 33780423
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered intranasally once a week for 5 weeks
Study: 33663737
Drug: Lower Dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower Dose Edoxaban Regimen (LDER) - 30 mg once daily (dose reduced to 15 mg in selective patients)
Study: 33663737
Drug: Higher Dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Dose Edoxaban Regimen (HDER) - 60 mg once daily (dose reduced to 30 mg in selective patients)
Study: 33663737
Drug: Lower Dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower Dose Edoxaban Regimen (LDER)
Study: 33757440
Drug: Neoadjuvant FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant FOLFIRINOX chemotherapy (8 cycles) followed by surgery without adjuvant treatment (arm A)
Study: 33757440
Drug: Neoadjuvant FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant FOLFIRINOX chemotherapy
Study: 32899447
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1000 mg daily) during the first six weeks of training.
Study: 32899447
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C supplementation (1000 mg daily) during the second six weeks of training.
Study: 34500184
Drug: Additional mood-stabilizing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional mood-stabilizing treatment
Study: 36189646
Drug: Oral extended-release
Normalized name: Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral extended-release nifedipine 30 mg every 24 hours
Study: 34961950
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg twice daily
Study: 34958123
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg b.i.d. enoxaparin
Study: 34958123
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg o.d. enoxaparin
Study: 32286883
Drug: Regular drug-eluting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular drug-eluting stent
Study: 36457363
Drug: Cognitive multisensory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive multisensory rehabilitation (CMR) for 6 weeks followed by 6 weeks of standard of care (no therapy) at home
Study: 36457363
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (no therapy) for 6 weeks followed by 6 weeks of CMR
Study: 32482335
Drug: sweet taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: sweet taste moisturizing gel
Study: 32482335
Drug: acid taste
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: acid taste with Japanese apricot extract moisturizing gel
Study: 32482335
Drug: Japanese apricot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Japanese apricot scent moisturizing gel
Study: 32482335
Drug: acid taste
Normalized name: 60 Second Taste
Approvals — FDA: no, EMA: no, PMDA: no
Description: acid taste with citric acid moisturizing gel
Study: 32482335
Drug: tasteless and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: tasteless and odorless moisturizing gel
Study: 32482335
Drug: control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: control (no gel administered)
Study: 33639517
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point acupressure treatment (acupressure points with Cowherb seeds)
Study: 33639517
Drug: Sham auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham auricular therapy (acupressure points without Cowherb seeds)
Study: 33639517
Drug: Auricular point
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auricular point acupressure treatment
Study: 33639517
Drug: Sham auricular
Normalized name: fluocinolone
DrugBank: Fluocinolone (DB12553)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham auricular therapy
Study: 34215606
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine (TCM) treatment, specific intervention details not provided.
Study: 34208055
Drug: Epinephrine group
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epinephrine group (125 µg epinephrine)
Study: 38241603
Drug: Adjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant endocrine therapy
Study: 36259380
Drug: Cabozantinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib (60 mg/day)
Study: 32143721
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid (TXA) 1950 mg with sublingual misoprostol 800 mcg
Study: 32143721
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with sublingual misoprostol 800 mcg
Study: 35980238
Drug: G Premio
Approvals — FDA: no, EMA: no, PMDA: no
Description: G Premio Bond (GP; universal) with two coats
Study: 35387686
Drug: Diet‐fish (hypocaloric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet‐fish (hypocaloric diet + 3 g/day of omega‐3 supplementation)
Study: 33992687
Drug: Saline spray
Normalized name: Saline Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline spray (control)
Study: 36287566
Drug: Kisspeptin administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kisspeptin administration (75-minute intravenous infusion of kisspeptin-54 at 1 nmol/kg/h)
Study: 36029059
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg/day for 22 weeks)
Study: 33113526
Drug: 1,000 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 U/kg Epo intravenously for 6 doses, followed by 400 U/kg Epo subcutaneously 3 times a week through 32 weeks post-menstrual age